Director, Clinical Quality Management at ADC Therapeutics - New Providence, NJ, US
ADC Therapeutics is a clinical-stage oncology biotechnology company leading the development and commercialization of next-generation antibody drug conjugates (ADCs) with highly potent and targeted pyrrolobenzodiazepine (PBD) dimer technology. These proprietary PBD-based ADCs are expected to provide a novel way to treat hematological cancers and solid tumors, address significant unmet medical needs, and improve the lives of patients with cancer. Our mission is to confront cancer with the full potential of our science to bring unique, targeted therapies and hope to patients and their families.